Len_safety_paper_post reviewers 2 no highlights.pdf (496.86 kB)
Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation
journal contribution
posted on 2023-06-10, 00:27 authored by John JonesJohn Jones, Graham Jackson, Jones PawlynMyeloma is the second most common hematological cancer, with 5800 cases per year diagnosed in the UK. Despite improved treatment it is still considered non-curable, although the median survival has increased from 3 to 8 years over the past 20 years. Treatment involves the use of induction therapy and consolidation with autologous stem cell transplant (ASCT) in patients deemed fit enough. Further attempts to improve outcomes include the use of maintenance therapy. This review details all trials in which lenalidomide has been used as maintenance following ASCT. PubMed searches included randomized control trials, observational cohort, reviews, and meta-analysis. Lenalidomide is a well-tolerated, oral agent that is associated with increased overall and progression free survival when used as maintenance following ASCT. Its use in this setting is FDA and EMA approved and is standard of care in Europe and North America. The early link between lenalidomide and second hematological cancers appears to be associated with use in combination with melphalan. There is an increase in non-melanoma skin cancers and solid tumors in the elderly but this has minimal impact on mortality. Lenalidomide use as part of combination maintenance is underway and may further improve outcomes.
History
Publication status
- Published
File Version
- Accepted version
Journal
Expert Opinion on Drug SafetyISSN
1474-0338Publisher
Taylor & FrancisExternal DOI
Department affiliated with
- Clinical and Experimental Medicine Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2021-07-23First Open Access (FOA) Date
2022-06-30First Compliant Deposit (FCD) Date
2021-08-27Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC